Deciphering Vaccines for COVID-19: where do we stand today?

Baviskar, Tushar; Raut, Dezaree; Bhatt, Lokesh Kumar

doi:10.1080/08923973.2020.1837867

Cited by 14 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They cause enteric, neurologic, respiratory and hepatic diseases [6]. Seven strains of coronavirus, which include OC43, 229E, HKU1, NL63, SARS-CoV, MERS-CoV, and SARS-CoV-2, are known to cause diseases in humans and new strains are emerging [7]. Out of these, four coronavirus strains, OC43, 229E, HKU1 and NL63, have been reported to affect the upper respiratory tract, causing mild-moderate and seasonal symptoms similar to common cold in individuals with an incompetent immune system [8].…”

Section: Introductionmentioning

confidence: 99%

Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management

Savla

Prabhavalkar

Bhatt

2021

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: SARS-CoV-2, the causative agent of COVID-19, attacks the immune system causing an exaggerated and uncontrolled release of pro-inflammatory mediators (cytokine storm). Recent studies propose an active role of coagulation disorders in disease progression. This hypercoagulability has been displayed by marked increase in D-dimer in hospitalized patients. Areas Covered: This review summarizes the pathogenesis of SARS-CoV-2 infection, generation of cytokine storm, the interdependence between inflammation and coagulation, its consequences and the possible management options for coagulation complications like venous thromboembolism (VTE), microthrombosis, disseminated intravascular coagulation (DIC), and systemic and local coagulopathy. We searched PubMed, Scopus, and Google Scholar for relevant reports using COVID-19, cytokine storm, and coagulation as keywords. Expert Opinion: A prophylactic dose of 5000-7500 units of low molecular weight heparin (LMWH) has been recommended for hospitalized COVID-19 patients in order to prevent VTE. Treatment dose of LMWH, based on disease severity, is being contemplated for patients showing a marked rise in levels of D-dimer due to possible pulmonary thrombi. Additionally, targeting PAR-1, thrombin, coagulation factor Xa and the complement system may be potentially useful in reducing SARS-CoV-2 infection induced lung injury, microvascular thrombosis, VTE and related outcomes like DIC and multi-organ failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management

Savla

Prabhavalkar

Bhatt

2021

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

show abstract

“…Generally, DNA vaccines have good stability profiles compared to mRNA and protein subunit vaccines and no risk of infection compared to live-attenuated virus-based vaccines (13). Also, they are cost-effective, easily produced, and can induce durable immune responses (61). ZyCoV-D is a plasmid DNA vaccine candidate developed by Zydus Cadila (Ahmedabad, India) (33,62).…”

Section: Plasmid Dna Vaccinementioning

confidence: 99%

Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration

2021

View full text Add to dashboard Cite

The dire need for safe and effective coronavirus disease (COVID-19) vaccines is met with many vaccine candidates being evaluated in pre-clinical and clinical studies. The COVID-19 vaccine candidates currently in phase 3 or phase 2/3 clinical trials as well as those that recently received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) and/or other regulatory agencies worldwide require either cold (i.e., 2-8°C) or even freezing temperatures as low as −70°C for storage and distribution. Thus, existing cold chain will struggle to support both the standard national immunization programs and COVID-19 vaccination. The requirement for cold chain is now a major challenge towards worldwide rapid mass vaccination against COVID-19. In this commentary, we stress that thermostabilizing technologies are available to enable cold chain-free vaccine storage and distribution, as well as potential needle-free vaccination. Significant efforts on thermostabilizing technologies must now be applied on next-generation COVID-19 vaccines for more cost-effective worldwide mass vaccination and COVID-19 eradication.

show abstract

“…The full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine is adjuvant with Matrix under the clinical evaluation of Phase 1/2NCT04368988) (Baviskar et al, 2020). Further, Adjuvanted recombinant protein (RBD-Dimer)NCT04445194 and recombinant spike protein with Advax TM adjuvant of NCT04453852 is under the phase 1 clinical evaluation ( Table 1) (Samrat et al, 2020).…”

Section: Vaccinementioning

confidence: 99%

The Perspective on Bio-Nano Interface Technology for Covid-19

Kamaraj¹

2020

Front. Nanotechnol.

View full text Add to dashboard Cite

The field of bio-nano interfaces paves the way for a better understanding, development, and implementation of the advanced biotechnological process. Interfacing biomolecules with the nanomaterials will result in the development of new tools and techniques that, in turn, will enable to explore the fundamental process at the nano level and fabricate cost-effective portable devices. Fascinating biomolecules like DNA, RNA and proteins in the regime of nanoscale are intelligent materials that are capable of storing the information and controlling the basic structure and function of the complex biological systems. Following this concept, the current pandemic situation would be a natural selection process, where the selective pressure is on the ssRNA of Covid-19 to choose the suitable progeny for survival. Consequently, the interaction of human DNA invoking response with Covid-19 happens at the nanoscale and it could be a better candidate to provoke combat against the virus. The extent of this interaction would give us the insights at the nanotechnological level to tackle the prevention, diagnosis and treatment for Covid-19. Herein, the possible features and obstacles in Covid-19 and a probable solution from the advent of nanotechnology are discussed to address the current necessity. Moreover, the perspective sustainable green graph mask that can be prepared using green plant extract/graphene (Bio-Nano composite mask) is suggested for the possible protection of virus-like Covid-19. The composite material will not only effectively trap the virus but also inactivate the virus due to the presence of antiviral compounds in the plant extracts.

show abstract

Deciphering Vaccines for COVID-19: where do we stand today?

Cited by 14 publications

References 25 publications

Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management

Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management

Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration

The Perspective on Bio-Nano Interface Technology for Covid-19

Contact Info

Product

Resources

About